Initiation of Dolutegravir Versus Efavirenz on Viral Suppression and Retention at 6 months: A Regression Discontinuity Design
Our estimates suggest early uptake of the revised treatment guidelines after implementation. Despite this, there was no meaningful change in viral suppression and retention rates at 6 months.
Authors
- Amy Zheng (ORCID: https://orcid.org/0000-0003-3048-3667)
- Mhairi Maskew (ORCID: https://orcid.org/0000-0003-4238-0200)
- François Venter (ORCID: https://orcid.org/0000-0002-4157-732X)
- Jacob Bor (ORCID: https://orcid.org/0000-0002-5112-8536)
- Alana T. Brennan (ORCID: https://orcid.org/0000-0002-7746-0668)
- Matthew P. Fox (ORCID: https://orcid.org/0000-0001-9887-0634)
- Pedro T. Pisa (ORCID: https://orcid.org/0000-0001-5188-5660)
- Emma M. Kileel (ORCID: https://orcid.org/0000-0003-0557-2035)
- Ross Greener (ORCID: https://orcid.org/0000-0001-8997-8977)
Institutions
- Boston University (US)
- University of the Witwatersrand (ZA)
- Right to Care (ZA)
- University of Pretoria (ZA)
Publication Details
- Journal
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1097/qai.0000000000003642
- Citations
- 1
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 1.40